[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100474372":3},{"organization":4,"outcomesModule":7,"designInfo":30,"detailedDescription":33,"studyPopulation":34,"armGroups":35,"interventions":41,"overallOfficials":29,"centralContacts":47,"locations":56,"responsibleParty":135,"collaborators":29,"id":138,"slug":139,"hasResults":140,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":29,"eligibilityCriteria":144,"healthyVolunteers":140,"sex":145,"minAge":146,"maxAge":29,"enrollmentInfo":147,"targetDuration":29,"studyType":150,"phases":29,"briefSummary":151,"conditions":152,"keywords":154,"overallStatus":59,"whyStopped":29,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},{"fullName":5,"class":6},"Guangdong Association of Clinical Trials","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":29},[9],{"measure":10,"description":11,"timeFrame":12},"Two-years disease free survival rates for patients with longitudinal undetectable MRD","The 2-year DFS rate of patients who maintain 2-years undetectable MRD.","2 year",[14,17,20,23,26],{"measure":15,"description":16,"timeFrame":12},"Two-years disease free survival rates for patients with six months longitudinal undetectable MRD","The 2-year DFS rate of patients who maintain 6-months undetectable MRD.",{"measure":18,"description":19,"timeFrame":12},"Two-years disease free survival rates for patients with 12-months longitudinal undetectable MRD","The 2-year DFS rate of patients who maintain 12-months undetectable MRD.",{"measure":21,"description":22,"timeFrame":12},"Two-years disease free survival rates for patients with 18-months longitudinal undetectable MRD","The 2-year DFS rate of patients who maintain 18-months undetectable MRD.",{"measure":24,"description":25,"timeFrame":12},"Two-years event-free survival rates for enrolled patients in two years","The events are defined as disease recurrence or detectable MRD.",{"measure":27,"description":28,"timeFrame":12},"Two-years disease free survival rates for patients who tested positive for MRD and failed screening during the two-round MRD tests.","The 2-year DFS rate of patients who tested positive for MRD and failed screening during the two-round MRD tests.",null,{"allocation":29,"interventionModel":29,"interventionModelDescription":29,"primaryPurpose":29,"observationalModel":31,"timePerspective":32,"maskingInfo":29},"COHORT","PROSPECTIVE","Stage IB-IIIA resected NSCLC patients will undergo two-round MRD tests after operation, first in 3-7 days and second in 1 month after operation. Patients who confirm two-round landmark undetectable MRD will be enrolled to be under close MRD and imaging monitoring without any adjuvant therapy. Patients who are MRD positive during the two-round MRD screening period will receive treatment and follow-up in accordance with Clinical Practice Guidelines.","Stage IB-IIIA NSCLC patients who after complete resection and undetectable landmark MRD.",[36],{"label":37,"type":29,"description":38,"interventionNames":39},"Undetectable MRD","Stage IB-IIIA NSCLC patients who after complete resection. And patients who maintain MRD negativity in two-round MRD landmark test (first in 3-7 days after surgery, second in 1 months ±7 days after surgery) will be enrolled. And patients will be under close dynamic monitoring at least two years.",[40],"Diagnostic Test: Molecular residual disease test",[42],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":29},"DIAGNOSTIC_TEST","Molecular residual disease test","OncoMRD Lung",[37],[48,53],{"name":49,"role":50,"phone":51,"phoneExt":29,"email":52},"Yi-Long Wu, M.D","CONTACT","020-83827812","syylwu@live.cn",{"name":54,"role":50,"phone":51,"phoneExt":29,"email":55},"Xue-Ning Yang, Ph.D","yangxuening@gdph.org.cn",[57,76,96,110,121],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"The First People's Hospital of Foshan","RECRUITING","Foshan","Guangdong","528000","China","CN",{"type":66,"coordinates":67},"Point",[68,69],113.13148,23.02677,{"lat":69,"lon":68},[72],{"name":73,"role":50,"phone":74,"phoneExt":29,"email":75},"Weiquan Gu","086-0757-83163155","gwquan@fsyyy.com",{"facility":77,"status":59,"city":78,"state":61,"zip":79,"country":63,"countryCode":64,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences","Guangzhou","510080",{"type":66,"coordinates":81},[82,83],113.25,23.11667,{"lat":83,"lon":82},[86,88,92,94],{"name":87,"role":50,"phone":29,"phoneExt":29,"email":29},"Wen-Zhao Zhong, MD",{"name":89,"role":50,"phone":90,"phoneExt":91,"email":52},"Yi-Long Wu, MD","+86 20 83827812","51221",{"name":89,"role":93,"phone":29,"phoneExt":29,"email":29},"PRINCIPAL_INVESTIGATOR",{"name":87,"role":95,"phone":29,"phoneExt":29,"email":29},"SUB_INVESTIGATOR",{"facility":97,"status":59,"city":98,"state":61,"zip":99,"country":63,"countryCode":64,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Shantou Centeral Hospital","Shantou","515031",{"type":66,"coordinates":101},[102,103],116.67876,23.35489,{"lat":103,"lon":102},[106],{"name":107,"role":50,"phone":108,"phoneExt":29,"email":109},"Yanlong Yang","086-0754-88550450","styylong@163.com",{"facility":111,"status":59,"city":98,"state":61,"zip":112,"country":63,"countryCode":64,"cosmosGeoPoint":113,"geoPoint":115,"contacts":116},"the First Affiliated Hospital of Shantou University Medical College","515041",{"type":66,"coordinates":114},[102,103],{"lat":103,"lon":102},[117],{"name":118,"role":50,"phone":119,"phoneExt":29,"email":120},"Zefeng Xie","086-0754-88258290","zefengxie@sina.com",{"facility":122,"status":59,"city":123,"state":61,"zip":124,"country":63,"countryCode":64,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"Zhongshan City People's Hospital","Zhongshan","528445",{"type":66,"coordinates":126},[127,128],113.37912,22.52306,{"lat":128,"lon":127},[131],{"name":132,"role":50,"phone":133,"phoneExt":29,"email":134},"Yi Liang, MD","086-0760-88823566","yiliang2020@qq.com",{"type":93,"investigatorFullName":136,"investigatorTitle":137,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Yi-Long Wu","Principal Investigator","100474372","adjuvant-therapy-omission-for-resected-nsclc-patients-with-longitudinal-undetectable-mrd-100474372",false,"NCT05457049","Adjuvant Therapy Omission for Resected NSCLC Patients With Longitudinal Undetectable MRD","Dynamic Observational Strategy for Stage IB-IIIA Non-Small Cell Lung Cancer Patients After Complete Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study","Inclusion Criteria:\n\n* Stage IB-IIIA non-small cell cancer patients who after complete resection.\n* ≥18 years.\n* Two-round MRD tests confirm landmark undetectable MRD.\n* Expected survival ≥12 weeks.\n* Expected survival ≥12 weeks.\n* ECOG PS 1-2.\n* Willing to accept MRD monitoring every 3 months for a total of 2 years after operation.\n\nExclusion Criteria:\n\n* Patients who had previously undergone radiotherapy or chemotherapy or any other anti-tumor therapy.\n* Patients with a history of other malignancies in the past 5 years.\n* Any unstable systemic disease (eg, active infection, high-risk hypertension, unstable angina, congestive heart failure, etc.).","ALL","18 Years",{"count":148,"type":149},180,"ESTIMATED","OBSERVATIONAL","Molecular residual disease (MRD) has strong relationship with clinical outcome in multiple solid tumors. Here, the investigators try to verify the negative predictive value of undetectable MRD, which is considered as a superior prognostic factor for resected NSCLC patients, and not requiring excessive adjuvant therapy. Stage IB-IIIA resected NSCLC patients with landmark and longitudinal undetectable MRD are enrolled and under close surveillance in this study.",[153],"Non Small Cell Lung Cancer",[155,156],"Molecular residual disease","Adjuvant therapy","2026-09-12",{"date":159,"type":160},"2026-09-16","ACTUAL",{"date":162,"type":160},"2022-08-01",{"date":164,"type":149},"2026-12-31",{"name":5,"class":6},5]